Entrada TherapeuticsTRDA
About: Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
Employees: 183
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
490% more call options, than puts
Call options by funds: $124K | Put options by funds: $21K
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
7% more funds holding
Funds holding: 103 [Q4 2024] → 110 (+7) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]
1.53% less ownership
Funds ownership: 86.52% [Q4 2024] → 84.99% (-1.53%) [Q1 2025]
33% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 42
48% less capital invested
Capital invested by funds: $560M [Q4 2024] → $290M (-$270M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Raghuram Selvaraju | 170%upside $20 | Buy Reiterated | 20 May 2025 |
Financial journalist opinion
Based on 3 articles about TRDA published over the past 30 days









